

Erratum

Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)

Pre-press 15 June 2020

Published 2 July 2020

Igor Stukalin, J. Connor Wells, Anna Fraccon, Felice Pasini, Camillo Porta, Aly-Khan A. Lalani, Sandy Srinivas, I. Alex Bowman, James Brugarolas, Jae-Lyun Lee, Frede Donskov, Benoit Beuselinck, Aristotelis Bamias, Brian I. Rini, Hao-Wen Sim, Neeraj Agarwal, Sun-Young Rha, Ravindran Kanavaran, Toni K. Choueiri and Daniel Y.C. Heng

[Kidney Cancer, 2(1) (2018), 31–36, DOI 10.3233/KCA-170020]
<https://content.iospress.com/articles/kidney-cancer/kca170020>

In Table 2 on page 34, the headings for OS (months) and PFS (months) should have been reversed. Thus the PFS (months) heading should be where the OS (months) heading is and the OS (months) heading should be where the PFS (months) heading is.

The corrected Table 2 with the right headings is visible below.

Table 2
Fourth-line progression free survival (PFS)/overall survival (OS)/best response

Fourth-line Drug	PFS (months)	OS (months)	Best Response			
			PR	SD	PD	CR
Everolimus	3.6 (3.0–4.7)	12.8 (9.5–18.5)	2/68	27/68	39/68	0/68
Sorafenib	3.9 (2.8–5.3)	11.4 (8.9–16.3)	8/71	30/71	33/71	0/71
Axitinib	7.3 (4.0–11.2)	18.0 (12.4–22.0)	3/46	24/46	19/46	0/46
Pazopanib	4.6 (3.4–6.8)	9.4 (7.3–13.8)	9/49	20/49	20/49	0/49
Sunitinib	5.3 (3.4–6.2)	12.1 (8.8–16.1)	16/65	24/65	25/65	0/65
Clinical Trial	4.4 (3.2–5.6)	14.2 (9.4–20.6)	4/42	20/42	18/42	0/42
Nivolumab	3.6 (3.9-NR)	NR (14.4-NR)	7/23	6/23	9/23	1/23
Total	4.4 (4.0–5.1)	12.8 (1.4–14.4)	49/364 13.5%	151/364 41.5%	163/364 44.8%	1/364 0.3%

CR= Complete Response; PR = Partial Response; SD = Stable Disease; PD = Progressive Disease.